After reporting first quarter losses of 9.9 million dollars, Delmar is poised to hit a bull run, likely due to continued global interest is pursuing medical research.
An old resistance level is reversing to support as sellers struggle to push prices down to previous levels. Ive laid out a long strategy to capitalize on short term growth.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在
使用条款阅读更多信息。